On Monday, CRISPR Therapeutics earned an upgrade to its Relative Strength (RS) Rating, from 86 to 93.
How To Use Stock Charts To Stay Profitable And Protected
This exclusive rating from Investor's Business Daily tracks market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price performance over the trailing 52 weeks compares to all the other stocks in our database.
Decades of market research reveals that the top-performing stocks typically have an 80 or higher RS Rating in the early stages of their moves.
CRISPR Therapeutics has climbed more than 5% past a 55.88 entry in a first-stage double bottom, meaning it's now out of a proper buy zone. Look for the stock to create a new buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average.
CRISPR Therapeutics reported 0% EPS growth last quarter, while sales growth came in at 74%. The next quarterly results are expected on or around Aug. 11.
The company earns the No. 88 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, Inhibrx Biosciences and TG Therapeutics are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
